TScan Therapeutics
  • About
    • Our Company
    • Management
    • Board of Directors
    • Scientific Advisory Board
    • Partners

    About TScan

    TScan is dedicated to changing lives by discovering new cancer targets and developing safe and effective T-cell therapies for patients.

  • Technology
    • Our Approach
    • TargetScan
    • ReceptorScan
    • T-Integrate Cell Engineering
    • Publications

    Technology

    TScan’s therapeutic approach is based on the central premise that we can learn from patients who are winning their fight against cancer in order to treat those who are not.

  • Investors and Media
  • Pipeline
  • Careers
  • About
    • Our Company
    • Management
    • Board of Directors
    • Scientific Advisory Board
    • Partners
  • Technology
    • Our Approach
    • TargetScan
    • ReceptorScan
    • T-Integrate Cell Engineering
    • Publications
  • Investors and Media
  • Pipeline
  • Careers

About

Leadership

  • Management
  • Board of Directors
  • Advisory Board

Stephen Elledge, Ph.D.

Scientific Co-founder

Tomasz Kula, Ph.D.

Scientific Co-founder of TScan

Kai Wucherpfennig, M.D., Ph.D.

Dana-Farber Cancer Institute

Malcolm Brenner, M.D., Ph.D.

Houston Methodist Hospital

Jerome Ritz, M.D.

Dana-Farber Cancer Institute

Chris Walsh, Ph.D.

Professor Emeritus, Medicine, Harvard Medical School

H. Benjamin Larman, Ph.D.

Assistant Professor of Pathology, Johns Hopkins Medicine

Aude Chapuis, M.D.

Assistant Member at Fred Hutch

Interested in joining our team? Explore Careers

©2023 TScan Therapeutics
  • Contact
  • Privacy policy
  • Terms and conditions